Annals of Clinical and Translational Neurology (Jul 2021)

Loss‐of‐function variants in Kv11.1 cardiac channels as a biomarker for SUDEP

  • Ming S. Soh,
  • Richard D. Bagnall,
  • Mark F. Bennett,
  • Lauren E. Bleakley,
  • Erlina S. Mohamed Syazwan,
  • A. Marie Phillips,
  • Mathew D. F. Chiam,
  • Chaseley E. McKenzie,
  • Michael Hildebrand,
  • Douglas Crompton,
  • Melanie Bahlo,
  • Christopher Semsarian,
  • Ingrid E. Scheffer,
  • Samuel F. Berkovic,
  • Christopher A. Reid

DOI
https://doi.org/10.1002/acn3.51381
Journal volume & issue
Vol. 8, no. 7
pp. 1422 – 1432

Abstract

Read online

Abstract Objective To compare the frequency and impact on the channel function of KCNH2 variants in SUDEP patients with epilepsy controls comprising patients older than 50 years, a group with low SUDEP risk, and establish loss‐of‐function KCNH2 variants as predictive biomarkers of SUDEP risk. Methods We searched for KCNH2 variants with a minor allele frequency of 20% reduction in maximal amplitude, were observed in 8.9% (8/90) SUDEP patients compared to 3.3% (11/332) epilepsy controls suggesting about threefold enrichment (nominal p = 0.04). KCNH2 variants that did not change channel function occurred at a similar frequency in SUDEP (2.2%; 2/90) and epilepsy control (2.7%; 9/332) cohorts (p > 0.99). Rare KCNH2 variants (<1% allele frequency) associated with greater loss of function and an ~11‐fold enrichment in the SUDEP cohort (nominal p = 0.03). In silico tools were unable to predict the impact of a variant on function highlighting the need for electrophysiological analysis. Interpretation These data show that loss‐of‐function KCNH2 variants are enriched in SUDEP patients when compared to an epilepsy population older than 50 years, suggesting that cardiac mechanisms contribute to SUDEP risk. We propose that genetic screening in combination with functional analysis can identify loss‐of‐function KCNH2 variants that could act as biomarkers of an individual’s SUDEP risk.